Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics director Robert B. Carter received an equity award in the form of restricted stock units. On May 20, 2026, he acquired 1,142 shares of Common Stock at a stated price of $0.00 per share, reflecting a grant or award rather than an open-market purchase.
After this award, Carter directly holds 3,853 shares of Quest Diagnostics common stock in total. The filing does not show any sales or derivative exercises, indicating this was a routine compensation-related equity grant to a board member rather than a trading decision in the market.
Gregg Vicky B reported acquisition or exercise transactions in this Form 4 filing.
Quest Diagnostics director Vicky B. Gregg received a compensation-related stock award. She was granted 1,142 shares of Quest Diagnostics common stock in the form of restricted stock units at no cash cost. Following this award, she directly holds 18,314 shares of Quest Diagnostics common stock.
Diaz Luis reported acquisition or exercise transactions in this Form 4 filing.
Quest Diagnostics director Luis Diaz received an equity grant in the form of restricted stock units. On May 20, 2026, he was awarded 1,142 shares of Quest Diagnostics common stock at no purchase price, increasing his directly held stake to 5,196 shares. This represents routine stock-based compensation rather than an open-market trade.
Quest Diagnostics director Timothy L. Main received an award of 1,142 shares of Common Stock in the form of restricted stock units on May 20, 2026. The award was granted at $0.00 per share as part of his compensation and is classified as a grant or award acquisition. Following this transaction, his directly owned Common Stock holdings increased to 27,439 shares.
Quest Diagnostics Inc. director Timothy C. Wentworth received an award of 1,142 shares of Common Stock in the form of restricted stock units. The grant carried a price of $0.00 per share and increased his directly owned holdings to 1,358 shares after the transaction.
The total also reflects shares previously acquired through dividend reinvestment under the Amended and Restated Deferred Compensation Plan for Directors, as noted in the footnotes. This is a compensation-related equity award rather than an open-market stock purchase or sale.
Quest Diagnostics director Tracey Doi received an equity award tied to her board service. She acquired 1,142 shares of Common Stock as a grant with no cash price per share, described in the footnotes as an award of restricted stock units. After this award and related dividend reinvestments, she directly holds 7,748 shares.
Quest Diagnostics director Timothy M. Ring received an award of 1,142 restricted stock units of common stock, classified as a grant or other acquisition with no cash price per share. After this award, he directly holds 31,140 shares, including shares acquired through dividend reinvestment under the Amended and Restated Deferred Compensation Plan for Directors.
Quest Diagnostics Inc. director Wright Lassiter III received an equity grant of 1,142 shares of common stock on May 20, 2026, reported as a restricted stock unit award. Following this grant, he directly holds 10,317 shares, which include shares acquired through dividend reinvestment under the Deferred Compensation Plan for Directors.
Quest Diagnostics director Denise M. Morrison received an award of 1,142 shares of Common Stock on May 20, 2026 as a grant of restricted stock units. The award was made at no cash cost per share and increased her direct holdings to 11,929 shares.
The total includes shares acquired through dividend reinvestment since her last Form 4 under the Amended and Restated Deferred Compensation Plan for Directors.
Quest Diagnostics Inc. director Gary M. Pfeiffer received an award of 1,142 restricted stock units of common stock on May 20, 2026 at no cash cost, as part of his director compensation. After this grant, his direct holdings total 31,005 shares, which include shares acquired through dividend reinvestment under the Amended and Restated Deferred Compensation Plan for Directors.